Issues and progress with protein kinase inhibitors for cancer treatment

Janet Dancey; Edward A Sausville

doi:10.1038/nrd1066

Issues and progress with protein kinase inhibitors for cancer treatment

Nat Rev Drug Discov. 2003 Apr;2(4):296-313. doi: 10.1038/nrd1066.

Authors

Janet Dancey¹, Edward A Sausville

Affiliation

¹ Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, National Cancer Institute, 6130 Executive Blvd, Room 7131, Rockville, Maryland 20852, USA. danceyj@ctep.nci.nih.gov

PMID: 12669029
DOI: 10.1038/nrd1066

Abstract

Identification of the key roles of protein kinases in cancer has led to extensive efforts to develop kinase inhibitors for the treatment of a wide range of cancers, and more than 30 such agents are now in clinical trials. Here, we consider the crucial issues in the development of kinase inhibitors for cancer, and discuss strategies to address the challenges raised by these issues in the light of preclinical and clinical experiences so far.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic
Drug Design
Drug Evaluation, Preclinical
Enzyme Inhibitors / pharmacology*
Enzyme Inhibitors / therapeutic use
Forecasting
Humans
Neoplasms / drug therapy*
Neoplasms / enzymology
Protein Kinase Inhibitors*
Signal Transduction / drug effects

Substances

Antineoplastic Agents
Enzyme Inhibitors
Protein Kinase Inhibitors